2025
Integrating epidemiology and genomics data to estimate the prevalence of acquired cysteine drug targets in the U.S. cancer patient population
Arun A, Liarakos D, Mendiratta G, Kim J, Goshua G, Olson P, Stites E. Integrating epidemiology and genomics data to estimate the prevalence of acquired cysteine drug targets in the U.S. cancer patient population. The Pharmacogenomics Journal 2025, 25: 5. PMID: 40044654, DOI: 10.1038/s41397-025-00364-3.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic AgentsCysteineGenomicsHumansMolecular Targeted TherapyMutationMutation RateMutation, MissenseNeoplasmsPrevalenceUnited StatesConceptsGenomic dataEstimates of mutation ratesSomatic missense mutationsGenomic informationPopulation-level estimatesCancer patient populationMissense mutationsNon-epidemiologicallyCancer patientsMutation ratePathogenic mutationsCysteine residuesCancer epidemiologyMutation-specificMutation abundanceDrug targetsMutationsIntegrates epidemiologyAbundancePatient populationEpidemiologyGenomePopulationTargeted therapyResiduesAdvancing drug development in myelodysplastic syndromes
Mina A, McGraw K, Cunningham L, Kim N, Jen E, Calvo K, Ehrlich L, Aplan P, Garcia-Manero G, Foran J, Garcia J, Zeidan A, DeZern A, Komrokji R, Sekeres M, Scott B, Buckstein R, Tinsley-Vance S, Verma A, Wroblewski T, Pavletic S, Norsworthy K. Advancing drug development in myelodysplastic syndromes. Blood Advances 2025, 9: 1095-1104. PMID: 39786387, PMCID: PMC11914162, DOI: 10.1182/bloodadvances.2024014865.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic AgentsClinical Trials as TopicDrug DevelopmentHumansMyelodysplastic SyndromesConceptsAllogeneic hematopoietic stem cell transplantationHematopoietic stem cell transplantationEnd pointsStem cell malignanciesTime-to-event end pointsStem cell transplantationUS Food and Drug AdministrationTreatment of patientsFood and Drug AdministrationClinical trial designDrug developmentMyelodysplastic syndromeCell transplantationCurative therapyRisk stratificationPoor prognosisCell malignancyTransformative therapiesDrug AdministrationBiomarker developmentResponse definitionsTrial designFunctional assessmentTherapyPatientsEfficacy of cannabinoids for the prophylaxis of chemotherapy-induced nausea and vomiting—a systematic review and meta-analysis
Chow R, Basu A, Kaur J, Hui D, Im J, Prsic E, Boldt G, Lock M, Eng L, Ng T, Zimmermann C, Scotte F. Efficacy of cannabinoids for the prophylaxis of chemotherapy-induced nausea and vomiting—a systematic review and meta-analysis. Supportive Care In Cancer 2025, 33: 193. PMID: 39953210, PMCID: PMC11828838, DOI: 10.1007/s00520-025-09251-w.Peer-Reviewed Original ResearchMeSH KeywordsAntiemeticsAntineoplastic AgentsCannabinoidsHumansNauseaNeoplasmsRandomized Controlled Trials as TopicVomitingConceptsChemotherapy-induced nausea and vomitingEfficacy of cannabinoidsTHC:CBDMeta-analysisPrevention of chemotherapy-induced nausea and vomitingProphylaxis of chemotherapy-induced nausea and vomitingChemotherapy-induced nausea and vomiting controlControlled trialsCochrane Central Register of Controlled TrialsCentral Register of Controlled TrialsRegister of Controlled TrialsNausea and vomitingChemotherapy-induced nauseaMethodsA literature searchCochrane Central RegisterComplete responseRandomized controlled trialsNo vomitingAdjunctive therapyRescue medicationAntiemetic regimensComposite endpointSubgroup analysisCannabinoidSecondary preventionHeme promotes venetoclax resistance in multiple myeloma through MEK-ERK signaling and purine biosynthesis
Nair R, Vu A, Freer A, Bhatia K, Wang D, Savani M, Matulis S, Lonial S, Jaye D, Boise L, Seo S, Corson T, Nooka A, Bhatt S, McBrayer S, Gupta V, Hu X, Barwick B, Reddi A, Shanmugam M. Heme promotes venetoclax resistance in multiple myeloma through MEK-ERK signaling and purine biosynthesis. Blood 2025, 145: 732-747. PMID: 39693611, DOI: 10.1182/blood.2024025690.Peer-Reviewed Original ResearchConceptsElectron transport chainBcl-2Heme biosynthesisBCL-2 antagonismElectron transport chain activityIron-containing prosthetic groupMultiple myelomaB-cell lymphoma 2MEK-ERK signalingGene signatureActivation of prosurvivalApoptotic thresholdPurine biosynthesisPenultimate enzymePyrimidine biosynthesisMetabolic rewiringTransport chainProtein kinaseMultiple Myeloma Research Foundation CoMMpass studyBiosynthesisPurine synthesisGenetic profilePrimary MM cellsProsthetic groupProgression-free survivalPatient-reported strategies for prevention and treatment of chemotherapy-induced peripheral neuropathy
Hertz D, Tanay M, Tofthagen C, Rossi E, Bernasconi D, Sheffield K, Carlson M, Nekhlyudov L, Grech L, Von Ah D, Mayo S, Ruddy K, Chan A, Alberti P, Lustberg M. Patient-reported strategies for prevention and treatment of chemotherapy-induced peripheral neuropathy. Supportive Care In Cancer 2025, 33: 142. PMID: 39899120, DOI: 10.1007/s00520-025-09190-6.Peer-Reviewed Original ResearchConceptsSelf-reported peripheral neuropathyCross-sectional online surveyGuideline-recommended strategyEvidence of effectivenessNon-prescribed medicationTreating CIPNPurposeChemotherapy-induced peripheral neuropathyChemotherapy-induced peripheral neuropathyPeripheral neuropathyClinical teamStrategies patientsPrescription medicationsNeurotoxic chemotherapy treatmentMultinational AssociationDescriptive statisticsPrescribed medicationsSurvey participantsPrevention strategiesGuideline-recommendedTreatment of chemotherapy-induced peripheral neuropathyOnline surveyCIPNDebilitating toxicityImprove treatment outcomesMedicationInsights into treatment of patients with mycosis fungoides or Sézary syndrome using mogamulizumab
Foss F, Kim Y, Scarisbrick J, Akilov O, Ristuccia R, Dwyer K, Wu W, Bagot M. Insights into treatment of patients with mycosis fungoides or Sézary syndrome using mogamulizumab. Journal Of Dermatological Treatment 2025, 36: 2438794. PMID: 39894454, DOI: 10.1080/09546634.2024.2438794.Peer-Reviewed Original ResearchConceptsMogamulizumab-associated rashConcomitant steroid useSezary syndromeAdvanced diseaseMycosis fungoidesSteroid useResponse to mogamulizumabProportion of patientsPercentage of patientsTreatment of patientsConcomitant steroidsRelapsed/refractory patientsLong-term responseMogamulizumabNext treatmentPatient characteristicsPatientsLymphopeniaVorinostatPatient responseFungoidesPFSMycosisSyndromeTreatmentDiagnosis of cancer therapy-related cardiovascular toxicities: A multimodality integrative approach and future developments
Travers S, Alexandre J, Baldassarre L, Salem J, Mirabel M. Diagnosis of cancer therapy-related cardiovascular toxicities: A multimodality integrative approach and future developments. Archives Of Cardiovascular Diseases 2025, 118: 185-198. PMID: 39947997, DOI: 10.1016/j.acvd.2024.12.012.Peer-Reviewed Original ResearchConceptsCardio-oncologyCardiovascular toxicityCardiovascular imagingMultimodality cardiovascular imagingCancer risk factorsIncrease diagnostic accuracyPrognostic stratificationNatriuretic peptideSerum biomarkersTherapy schemesDiagnostic accuracyCancer therapyRhythm disordersRisk factorsCardiovascular diseaseBiomarkersMultimodal integrated approachCancerOmics approachesToxicityRhythmTherapyTroponinSerumDiagnosisHow to Use Imaging: Complex Cases of Atherosclerosis, Myocardial Inflammation, and Cardiomyopathy in Cardio-Oncology
Khattab M, Baig M, Zarif T, Barac A, Ferencik M, Henry M, Lopez-Mattei J, Redheuil A, Salem J, Scherrer-Crosbie M, Yang E, Baldassarre L. How to Use Imaging: Complex Cases of Atherosclerosis, Myocardial Inflammation, and Cardiomyopathy in Cardio-Oncology. Circulation Cardiovascular Imaging 2025, 18: e015981. PMID: 39772610, DOI: 10.1161/circimaging.124.015981.Peer-Reviewed Original ResearchConceptsCardio-oncologyCases of atherosclerosisCardiac magnetic resonance imagingCoronary computed tomography angiographySingle-photon emission computed tomographyImmune checkpoint inhibitorsLeft ventricular dysfunctionMultimodality cardiac imagingTyrosine kinase inhibitorsCardiac imaging modalitiesComputed tomography angiographyRisk of cardiovascular diseaseEmission computed tomographyPositron emission tomographyMagnetic resonance imagingCheckpoint inhibitorsVentricular dysfunctionMyocardial inflammationCoronary vasospasmAccelerated atherosclerosisKinase inhibitorsPatient populationDiagnosing such pathologiesCancer therapyCardiac imagingMAT2A inhibitor AG-270/S095033 in patients with advanced malignancies: a phase I trial
Gounder M, Johnson M, Heist R, Shapiro G, Postel-Vinay S, Wilson F, Garralda E, Wulf G, Almon C, Nabhan S, Aguado-Fraile E, He P, Romagnoli M, Hossain M, Narayanaswamy R, Sadou-Dubourgnoux A, Cooper M, Askoxylakis V, Burris H, Tabernero J. MAT2A inhibitor AG-270/S095033 in patients with advanced malignancies: a phase I trial. Nature Communications 2025, 16: 423. PMID: 39762248, PMCID: PMC11704051, DOI: 10.1038/s41467-024-55316-5.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic AgentsEnzyme InhibitorsFemaleHumansMaleMaximum Tolerated DoseMethionine AdenosyltransferaseMiddle AgedNeoplasmsS-AdenosylmethionineConceptsAdvanced malignanciesEvidence of clinical activityPaired tumor biopsiesTreatment-related toxicityPhase I trialPhase 1 trialFirst-in-humanLiver function testsProof-of-mechanismHomozygous MTAP deletionPlasma SAM concentrationsPartial responseConcentrations of S-adenosylmethionineTumor biopsiesI trialSafety profileMTAP deletionHomozygous deletionMAT2A inhibitionClinical activityPlasma concentrationsFunction testsPatientsSecondary objectivesMaximal reduction
2024
Efficacy and Safety of Denileukin Diftitox-Cxdl, an Improved Purity Formulation of Denileukin Diftitox, in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma
Foss F, Kim Y, Prince H, Akilov O, Querfeld C, Seminario-Vidal L, Fisher D, Kuzel T, Yannakou C, Geskin L, Feldman T, Sokol L, Allen P, Dang N, Cabanillas F, Wong H, Ooi C, Xing D, Sauter N, Singh P, Czuczman M, Duvic M. Efficacy and Safety of Denileukin Diftitox-Cxdl, an Improved Purity Formulation of Denileukin Diftitox, in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma. Journal Of Clinical Oncology 2024, 43: 1198-1209. PMID: 39700456, PMCID: PMC11949209, DOI: 10.1200/jco-24-01549.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaTreatment-emergent adverse eventsTime to responseT-cell lymphomaTumor burdenRefractory cutaneous T-cell lymphomaEnd pointsEfficacy end pointCapillary leak syndromePrimary efficacy analysisSecondary end pointsHuman interleukin-2Unmet medical needMedian DoRSystemic therapyInfusion reactionsOpen-labelDenileukin diftitoxEfficacy analysisAdverse eventsInterleukin-2Safety resultsQ1-Q3PatientsResponse rateDevelopment of a small molecule-based two-photon photosensitizer for targeting cancer cells
Lee D, Cao Y, Juvekar V, Sauraj, Noh C, Shin S, Liu Z, Kim H. Development of a small molecule-based two-photon photosensitizer for targeting cancer cells. Journal Of Materials Chemistry B 2024, 12: 12232-12238. PMID: 39469993, DOI: 10.1039/d4tb01706d.Peer-Reviewed Original ResearchConceptsTarget cancer cellsReactive oxygen speciesPhotodynamic therapyCancer cellsDiverse cell linesInduced ROS productionColon cancer tissuesTwo-photon (TPCell deathLow dark toxicityCancer modelsTwo-photon photosensitizerROS productionCancer selectivityInduce cell damageThree-dimensional spheroidsCell linesTP excitationImaging-guided photodynamic therapyCancer tissuesOxygen speciesTP-PDTG9a/DNMT1 co-targeting inhibits non-small cell lung cancer growth and reprograms tumor cells to respond to cancer-drugs through SCARA5 and AOX1
Exposito F, Redrado M, Serrano D, Calabuig-Fariñas S, Bao-Caamano A, Gallach S, Jantus-Lewintre E, Diaz-Lagares A, Rodriguez-Casanova A, Sandoval J, San Jose-Eneriz E, Garcia J, Redin E, Senent Y, Leon S, Pio R, Lopez R, Oyarzabal J, Pineda-Lucena A, Agirre X, Montuenga L, Prosper F, Calvo A. G9a/DNMT1 co-targeting inhibits non-small cell lung cancer growth and reprograms tumor cells to respond to cancer-drugs through SCARA5 and AOX1. Cell Death & Disease 2024, 15: 787. PMID: 39488528, PMCID: PMC11531574, DOI: 10.1038/s41419-024-07156-w.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerNon-small cell lung cancer patientsCM-272Treatment of non-small cell lung cancerReprogram tumor cellsAssociated with poor prognosisResponse to chemotherapyCell lung cancerCancer drugsMonitor tumor progressionOverexpression of G9aNSCLC cell linesLung cancer growthCancer drug sensitivityNon-small cell lung cancer growthNon-invasive biomarkersTumor volumeAntitumor efficacyTargeted therapyPoor prognosisCancer modelsTumor cellsInduce cell deathTumor progressionLung cancerScalp cooling therapy for chemotherapy-induced hair loss in patients with breast or gynecological cancers—an Asian tertiary institution experience
Lee V, Loh J, Hui F, Sundar R, Tan B, Lee M, Lin H, Ong L, Visvanadan N, Ow S, Wong A, Chan G, Lim S, Lim Y, Tan D, Ang Y, Choo J, Lee M, Ngoi N, Lee S, Paxman R, Parker A, Lee Y, Lim J. Scalp cooling therapy for chemotherapy-induced hair loss in patients with breast or gynecological cancers—an Asian tertiary institution experience. Supportive Care In Cancer 2024, 32: 762. PMID: 39482416, DOI: 10.1007/s00520-024-08940-2.Peer-Reviewed Original ResearchConceptsHair preservationGynaecological cancerChemotherapy-induced alopeciaScalp cooling therapyHair regrowthCooling therapyTaxane-based chemotherapyCycles of chemotherapyAnthracycline based chemotherapyResultsEighty-three patientsGrade (GComfort scoresWeekly paclitaxelPaclitaxel regimenBased chemotherapyComfort levelChemotherapy cyclesTerminology criteriaAdverse eventsHistorical controlsInstitutional experienceChemotherapyChemotherapy-induced hair lossDrug infusionResultsEighty-threeMulti-day vs single-day dexamethasone for the prophylaxis of chemotherapy-induced nausea and vomiting: systematic review and meta-analysis
Chow R, Celio L, Im J, Caini S, Eng L, Prsic E, Scotté F, Aapro M. Multi-day vs single-day dexamethasone for the prophylaxis of chemotherapy-induced nausea and vomiting: systematic review and meta-analysis. Supportive Care In Cancer 2024, 32: 736. PMID: 39432169, DOI: 10.1007/s00520-024-08934-0.Peer-Reviewed Original ResearchMeSH KeywordsAntiemeticsAntineoplastic AgentsDexamethasoneDrug Administration ScheduleHumansNauseaNeoplasmsRandomized Controlled Trials as TopicVomitingConceptsDexamethasone-sparing regimenChemotherapy-induced nausea and vomitingModerately emetogenic chemotherapyHighly emetogenic chemotherapyRandomized controlled trialsComplete responseMeta-analysisEmetogenic chemotherapyNo vomitingRescue medicationProphylaxis of chemotherapy-induced nausea and vomitingSystematic reviewSchedule of dexamethasoneNausea and vomitingChemotherapy-induced nauseaResultsTen trialsAntiemetic regimenCumulative meta-analysisEffect estimatesSafety profileComprehensive systematic reviewMethodsOvid MEDLINERegimensAdult cancer patientsCancer patientsA brave new framework for glioma drug development
Hotchkiss K, Karschnia P, Schreck K, Geurts M, Cloughesy T, Huse J, Duke E, Lathia J, Ashley D, Nduom E, Long G, Singh K, Chalmers A, Ahluwalia M, Heimberger A, Bagley S, Todo T, Verhaak R, Kelly P, Hervey-Jumper S, de Groot J, Patel A, Fecci P, Parney I, Wykes V, Watts C, Burns T, Sanai N, Preusser M, Tonn J, Drummond K, Platten M, Das S, Tanner K, Vogelbaum M, Weller M, Whittle J, Berger M, Khasraw M. A brave new framework for glioma drug development. The Lancet Oncology 2024, 25: e512-e519. PMID: 39362262, DOI: 10.1016/s1470-2045(24)00190-6.Peer-Reviewed Original ResearchConceptsBrain tumorsBenefits of biopsyBrain tumor therapyLiquid biopsy technologiesTissue samplesPostoperative deficitsBiopsy techniqueBiopsy technologyEffective therapySurgical trialsClinical trialsTumor therapyResistance mechanismsTumorTherapyPatientsDrug developmentTissue analysisBrainTrialsTissueBiopsyGliomaRegulatory agenciesBarriers to and facilitators of improving physical activity and nutrition behaviors during chemotherapy for breast cancer: a sequential mixed methods study
Puklin L, Irwin M, Sanft T, Ferrucci L, Harrigan M, McGowan C, Cartmel B, Zupa M, Winer E, Deyling M, Ligibel J, Basen-Engquist K, Spiegelman D, Sharifi M. Barriers to and facilitators of improving physical activity and nutrition behaviors during chemotherapy for breast cancer: a sequential mixed methods study. Supportive Care In Cancer 2024, 32: 590. PMID: 39141176, DOI: 10.1007/s00520-024-08789-5.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic AgentsBreast NeoplasmsExerciseFemaleHealth BehaviorHumansLife StyleMiddle AgedQualitative ResearchSurveys and QuestionnairesConceptsPhysical activityLifestyle interventionSelf-reported PA questionnaireSelf-reported diet qualityBreast cancerHealthy Eating Index-2015Stage I-III breast cancerBenefits of PASequential mixed methods studyI-III breast cancerChemotherapy-related symptomsMixed methods studyThematic content analysisBehavioral goalsSense of controlBody mass indexPA questionnaireSemi-structured interviewsMean body mass indexTranscribed verbatimIntervention armTailored educationDiet qualityNutritional behaviorMental benefitsGastrointestinal Cancer Therapy and Cardiotoxicity
Leiva O, Zarif T, Alvarez-Cardona J. Gastrointestinal Cancer Therapy and Cardiotoxicity. Current Treatment Options In Oncology 2024, 25: 1203-1209. PMID: 39102169, DOI: 10.1007/s11864-024-01236-x.Peer-Reviewed Original ResearchConceptsTyrosine kinase inhibitorsGastrointestinal cancerAnti-vascular endothelial growth factorHeterogeneous group of cancersCancer-specific outcomesEndothelial growth factorGroup of cancersConventional chemotherapyCardiotoxic therapiesTargeted therapyPotential cardiotoxicityKinase inhibitorsRisk factorsCardiovascular diseaseGrowth factorCancerHeterogeneous groupTherapyCardiotoxicityImmunotherapyChemotherapyPatientsAdjuvant Everolimus in Non–Clear Cell Renal Cell Carcinoma
Gulati S, Tangen C, Ryan C, Vaishampayan U, Shuch B, Barata P, Pruthi D, Bergerot C, Tripathi A, Lerner S, Thompson I, Lara P, Pal S. Adjuvant Everolimus in Non–Clear Cell Renal Cell Carcinoma. JAMA Network Open 2024, 7: e2425288. PMID: 39106067, PMCID: PMC11304111, DOI: 10.1001/jamanetworkopen.2024.25288.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic AgentsCarcinoma, Renal CellChemotherapy, AdjuvantEverolimusFemaleHumansKidney NeoplasmsMaleMiddle AgedNephrectomyConceptsChromophobe renal cell carcinomaRecurrence-free survivalPapillary renal cell carcinomaRenal cell carcinomaNon-clear cell renal cell carcinomaResected renal cell carcinomaCell renal cell carcinomaOverall survivalWeeks of treatmentCell carcinomaAdverse eventsClinical trialsHazard ratioPhase 3 randomized clinical trialWeeks of everolimusHigher adverse eventsRate of adverse eventsIntermediate-high riskIntervention groupVery-high-riskCox regression modelsPotential treatment benefitsClinical trial dataTreatment-naivePartial nephrectomyUnlocking the Potential: Biomarkers of Response to Antibody-Drug Conjugates.
Ascione L, Guidi L, Prakash A, Trapani D, LoRusso P, Lou E, Curigliano G. Unlocking the Potential: Biomarkers of Response to Antibody-Drug Conjugates. American Society Of Clinical Oncology Educational Book 2024, 44: e431766. PMID: 38828973, DOI: 10.1200/edbk_431766.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic AgentsBiomarkers, TumorDrug Resistance, NeoplasmHumansImmunoconjugatesMolecular Targeted TherapyNeoplasmsTreatment OutcomeConceptsAntibody-drug conjugatesTumor sitePredictive biomarkersAntigen expressionLack of robust predictive biomarkersSelection of targeted therapiesRobust predictive biomarkersTarget antigen expressionTumor antigen expressionCancer treatment landscapeBiomarkers of responseImprove patient selectionTumor intrinsic featuresBiomarkers of safetyUnique adverse eventsIdentification of patientsPopulation of patientsClinically actionable biomarkersSmall-molecule agentsPatient-centred outcomesTreatment landscapeBiomarker-drivenTreatment resistanceClinical benefitPatient selectionMicrotubule-Targeting Agents: Disruption of the Cellular Cytoskeleton as a Backbone of Ovarian Cancer Therapy
Danziger M, Noble H, Roque D, Xu F, Rao G, Santin A. Microtubule-Targeting Agents: Disruption of the Cellular Cytoskeleton as a Backbone of Ovarian Cancer Therapy. Advances In Experimental Medicine And Biology 2024, 1452: 1-19. PMID: 38805122, DOI: 10.1007/978-3-031-58311-7_1.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntineoplastic AgentsCytoskeletonDrug Resistance, NeoplasmFemaleHumansMicrotubulesOvarian NeoplasmsTubulin ModulatorsConceptsOvarian cancer therapyCancer therapyTargets of anti-cancer therapyIntracellular traffickingCellular processesCellular cytoskeletonMicrotubule-active agentsAnti-cancer therapyMicrotubule-stabilizing agentEffective regimenDynamic polymersDevelopment of resistanceB-tubulinTherapeutic challengeMicrotubulesRecurrent settingTherapyEukaryotesCytoskeletonMitosisHeterodimerMotilityTraffickingRegimensReplication
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply